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Abstract 
Rare genetic variants in LDLR, APOB and PCSK9 are known causes of familial hypercholesterolaemia 
and it is expected that rare variants in other genes will also have effects on hyperlipidaemia risk 
although such genes remain to be identified. The UK Biobank consists of a sample of 500,000 
volunteers and exome sequence data is available for 50,000 of them. 11,490 of these were classified 
as hyperlipidaemia cases on the basis of having a relevant diagnosis recorded and/or taking lipid-
lowering medication while the remaining 38,463 were treated as controls. Variants in each gene 
were assigned weights according to rarity and predicted impact and overall weighted burden scores 
were compared between cases and controls, including population principal components as 
covariates. One biologically plausible gene, HUWE1, produced statistically significant evidence for 
association after correction for testing 22,028 genes with a signed log10 p value (SLP) of -6.15, 
suggesting a protective effect of variants in this gene. Other genes with uncorrected p<0.001 are 
arguably also of interest, including LDLR (SLP=3.67), RBP2 (SLP=3.14), NPFFR1 (SLP=3.02) and ACOT9 
(SLP=-3.19). Gene set analysis indicated that rare variants in genes involved in metabolism and 
energy can influence hyperlipidaemia risk. Overall, the results provide some leads which might be 
followed up with functional studies and which could be tested in additional data sets as these 
become available. This research has been conducted using the UK Biobank Resource. 
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Introduction 
Hyperlipidaemia is an important risk factor for cardiovascular disease which is modified by genetic 
variation and some of the genes involved have been identified (Sharifi et al., 2017). Rare variants 
with a large dominant effect in LDLR, APOB and PCSK9 cause 40% of cases of familial 
hypercholesterolaemia (FH), a severe form of hyperlipidaemia. A whole genome sequencing study of 
over 16,000 subjects failed to identify rare variants in any additional genes influencing lipid levels, 
though yielded a total of 26 loci containing common variants which were genome-wide significant, 
largely replicating findings from previous genome wide association studies (GWAS) (Natarajan et al., 
2018; Willer et al., 2013). A GWAS of medication usage in 320,000 European UK Biobank participants 
identified 55 independent SNPs associated with taking statins, including 19 previously shown to be 
associated with low density lipoprotein cholesterol (LDLC), and showed that these were enriched in 
a number of gene sets involved with lipid metabolism (Wu et al., 2019). Another GWAS of European 
UK Biobank participants identified hundreds of genome-wide significant independent SNPs 
associated with lipid levels (Richardson et al., 2020).  
Although common genetic variation makes a substantial overall contribution to the variance in lipid 
levels, selection pressures mean that common variants individually have small effects and it can be 
difficult to elucidate the biological mechanisms underlying their association. It is to be expected that 
rare variants will also have effects and it is possible that some of them might have large effect sizes. 
Such analyses may be better able to identify specific genes rather than genetic loci and may indicate 
a direction of effect. The UK Biobank sample (http://www.ukbiobank.ac.uk/about-biobank-uk/) 
contains information about medication usage and clinical diagnoses, both as reported by 
participants and as extracted from their health records. Exome sequence data is available for 50,000 
subjects and a gene-wise weighted burden analysis of rare variants was carried out to attempt to 
identify genes associated with a hyperlipidaemia phenotype, defined as subjects with a diagnosis of 
hyperlipidaemia and/or taking cholesterol-lowering medication. 
Methods 
The UK Biobank dataset was downloaded along with the variant call files for 49,953 subjects who 
had undergone exome-sequencing and genotyped using the GRCh38 assembly with coverage 20X at 
94.6% of sites on average (Hout et al., 2019). UK Biobank had obtained ethics approval from the 
Research Ethics Committee (REC; approval number: 11/NW/0382) and informed consent from all 
participants. All variants were annotated using the standard software packages VEP, PolyPhen and 
SIFT (Adzhubei et al., 2013; Kumar et al., 2009; McLaren et al., 2016).  To obtain population principal 
components reflecting ancestry, version 1.90beta of plink (https://www.cog-genomics.org/plink2) 
was run with the options --maf 0.1 --pca header tabs --make-rel (Chang et al., 2015; Purcell et al., 
2007, 2009). 
The hyperlipidaemia phenotype was determined from four sources in the dataset: self-reported high 
cholesterol; reporting taking cholesterol lowering medication; reporting taking a named statin; 
having an ICD10 diagnosis for hyperlipidaemia in hospital records or as a cause of death. Subjects in 
any of these categories were deemed to be cases with hyperlipidaemia while all other subjects were 
taken to be controls. 
The SCOREASSOC program was used to carry out a weighted burden analysis to test whether, in each 
gene, sequence variants which were rarer and/or predicted to have more severe functional effects 
occurred more commonly in cases than controls. Attention was restricted to rare variants with minor 
allele frequency (MAF) <= 0.01. As previously described, variants were weighted by MAF so that 
variants with MAF=0.01 were given a weight of 1 while very rare variants with MAF close to zero 
were given a weight of 10 (Curtis, 2020). Variants were also weighted according to their functional 
annotation using the default weights provided with the GENEVARASSOC program, which was used to 
generate input files for weighted burden analysis by SCOREASSOC (Curtis, 2016, 2012). For example, 
a weight of 5 was assigned for a synonymous variant, 10 for a non-synonymous variant and 20 for a 
stop gained variant. Additionally, 10 was added to the weight if the PolyPhen annotation was 
possibly or probably damaging and also if the SIFT annotation was deleterious, meaning that a non-
synonymous variant annotated as both damaging and deleterious would be assigned an overall 
weight of 30. The full set of weights is shown in Supplementary Table S1, copied from the previous 
reports which used this method (Curtis et al., 2019, 2018). The weight due to MAF and the weight 
due to functional annotation were then multiplied together to provide an overall weight for each 
variant. Variants were excluded if there were more than 10% of genotypes missing in the controls or 
if the heterozygote count was smaller than both homozygote counts in the controls. If a subject was 
not genotyped for a variant then they were assigned the subject-wise average score for that variant. 
For each subject a gene-wise weighted burden score was derived as the sum of the variant-wise 
weights, each multiplied by the number of alleles of the variant which the given subject possessed. 
For variants on the X chromosome, hemizygous males were treated as homozygotes.  
For each gene, a ridge regression analysis was carried out with lamda=1 to test whether the gene-
wise variant burden score was associated with the hyperlipidaemia phenotype. To do this, 
SCOREASSOC first calculates the likelihood for the phenotypes as predicted by the first 20 population 
principal components and then calculates the likelihood using a model which additionally 
incorporates the gene-wise burden scores. It then carries out a likelihood ratio test assuming that 
twice the natural log of the likelihood ratio follows a chi-squared distribution with one degree of 
freedom to produce a p value. The statistical significance is summarised as a signed log p value (SLP) 
which is the log base 10 of the p value given a positive sign if the score is higher in cases and 
negative if it is higher in controls. We have shown that incorporating population principal 
components in this way satisfactorily controls for test statistic inflation when applied to this 
heterogeneous dataset (Curtis, 2020). 
Gene set analyses were carried out using the 1454 "all GO gene sets, gene symbols" pathways as 
listed in the file c5.all.v5.0.symbols.gmt downloaded from the Molecular Signatures Database at 
http://www.broadinstitute.org/gsea/msigdb/collections.jsp (Subramanian et al., 2005). For each set 
of genes, the natural logs of the gene-wise p values were summed according to Fisher’s method to 
produce a chi-squared statistic with degrees of freedom equal to twice the number of genes in the 
set. The p value associated with this chi-squared statistic was expressed as a minus log10 p (MLP) as 
a test of association of the set with the hyperlipidaemia phenotype. 
Results  
There were 11,490 cases with a diagnosis of hyperlipidaemia and/or taking cholesterol-lowering 
medication and 38,463 controls. There were 22,028 genes for which there were qualifying variants 
and the quantile-quantile (QQ) plot for the SLPs obtained for each gene is shown in Figure 1. This 
shows that the test is well-behaved and conforms well with the expected distribution.  
Table 1 shows the results for all genes with an absolute value of SLP exceeding 3 (equivalent to 
p<0.001). By chance, from 22,028 genes one would expect 11 to have SLP greater than 3 and 11 to 
have SLP less than -3, whereas the actual numbers are 15 and 28. Applying a Bonferroni correction 
to test for genome-wide statistical significance would yield a threshold of log10(22,028/0.05)=5.6 for 
the absolute value of the SLP and this is achieved by only two genes, HUWE1 and CXorf56. For both 
these genes the SLP was negative, indicating that rare, functional variants were enriched in controls 
compared with cases and suggesting that impairment of these genes might be protective against 
hyperlipidaemia. 
HUWE1 (SLP=-6.15) codes for an ubiquitin protein ligase which has functions in development and 
tumorigenesis and which regulates the ABCG1 and ABCG4 lipid transporters such that over-
expression of HUWE1 reduces ABCG1 and ABCG4 protein levels and their cholesterol export activity 
while silencing the gene has the reverse effects (Aleidi et al., 2015). It is also mediates the 
ubiquitination of peroxisome proliferator-activated receptor α (PPARα), thereby reducing its 
function (Zhao et al., 2018). PPARα is a transcriptional factor which promotes hepatic lipid 
catabolism by stimulating fatty acid oxidation and ketogenesis in response to nutrient starvation. 
CXorf56 (SLP=-5.61) is a brain expressed gene which is not well characterised but has recently been 
implicated as a cause of intellectual disability (Rocha et al., 2020). Subjects with variants damaging 
this gene are reported to have intellectual disability and sometimes related features including 
epilepsy and alopecia but there are no reports of abnormalities of lipid metabolism.  
No other gene was formally genome-wide significant and it is reasonable to assume that for most of 
those listed in the table the SLPs represent chance findings. However for a few it is possible that 
there is a real biological effect which is being picked up. The most obvious of these is LDLR, with 
SLP=3.67. It is well known that variants in this gene can cause familial hyperlipidaemia (Sharifi et al., 
2017). It is worth noting however that the other two genes implicated in autosomal dominant 
familial hyperlipidaemia, APOB (SLP=0.11) and PCSK9 (SLP=-0.66) did not produce any evidence of 
association. The same applies to HMGCR (SLP=-0.38), which codes for the target of statins. On 
inspection of the detailed output files, for all three of these genes there was a range of variants with 
different functionality and no general tendency for the distribution of the most functional variants to 
vary between cases and controls.  
Others of the genes with magnitude of SLP exceeding 3 (equivalent to p<0.001) which might be of 
interest are as follows. 
RBP2 (SLP=3.14) is expressed in the gut and its product is responsible for uptake of vitamin A but 
recent studies in mice have shown that it also influences body weight, the response to glucose 
challenge and hepatic triglyceride levels while Rbp2 deficient mice have increased adiposity, with 
larger adipocytes, and decreased energy expenditure (Lee et al., 2020). The authors suggest a 
signalling role for RBP2 and if similar mechanisms were present in humans then it is plausible that 
variants disrupting RBP2 could lead to increased risk of hyperlipidaemia. 
STAT5B (SLP=3.11) codes for a transcription factor which is responsible for mediating the signal from 
various ligands, including growth hormone, and is also involved in adipogenesis (Goupille et al., 
2016; Wakao et al., 2011). Two common variants in STAT5B, rs8082391 and rs8064638, have 
previously been reported to be associated with total cholesterol and low-density lipoprotein 
cholesterol while mice deficient in hepatic Stat5a/b had reduced serum cholesterol (Kornfeld et al., 
2011). Additionally, a small candidate gene study claimed that SNPs in STAT5B were associated with 
lipid changes in response to growth hormone replacement therapy (Makimura et al., 2011). 
However no SNPs close to STAT5B were genome-wide significantly associated with low density 
lipoprotein cholesterol or triglyceride levels in 180,000 UK Biobank subjects so the early SNP 
association results may have been false positives (Richardson et al., 2020). The mouse phenotype 
remains of interest, although it might suggest that variants in the gene should reduce, rather than 
increase, the risk of hyperlipidaemia 
NPFFR1 (SLP=3.02) codes for a receptor for a variety of neuropeptides including NPAF and NPFF and 
is expressed on adipocytes, where NPFF or NPAF treatment results in increased expression of 
adrenergic receptors and potentiation of the response to beta agonists to increase adenylyl cyclase 
activity (Lefrère et al., 2002). It is also expressed in the brain and NPFF has been shown to be 
anorexigenic in rats and chicks (Cline et al., 2007; Murase et al., 1996). Knockout of Npffr1 in mice 
has differential effects according to sex including increased susceptibility to high fat diet with 
impaired glucose tolerance in males but increased weight and sensitivity to obesogenic insults in 
females (Leon et al., 2018). Overall it seems possible that impaired functioning of this receptor might 
lead to metabolic abnormalities which predispose to hyperlipidaemia.  
ACOT9 (SLP=-3.19) codes for a mitochondrial acyl-CoA thioesterase which has recently been 
proposed to have a key role in liver lipogenesis and risk of non-alcoholic fatty liver disease (NAFLD) 
(Steensels et al., 2020). It is a regulator of lipid accumulation and its expression is higher in NAFLD 
patients, while Acot9 deficient mice are protected against weight gain, hepatic glucose production, 
steatosis and steatohepatitis in the setting of excess nutrition. These observations are consistent 
with the possibility that variants in ACOT9 might tend to be protective against metabolic responses 
resulting in hyperlipidaemia. 
GK (SLP=-3.31) codes for glycerol kinase and a number of variants in the gene have been reported to 
cause X-linked glycerol kinase deficiency syndromes which can very mild or which may involve 
symptoms including vomiting, hypoglycaemia, hyperketonaemia and intellectual disability (Sjarif et 
al., 1998). Its product has recently been shown to enhance hepatic liver metabolism and increased 
expression in mice leads to increased blood levels of cholesterol and triglycerides (Miao et al., 2020). 
Thus it is possible that variants mildly impairing GK but not sufficient to cause clinical glycerol kinase 
deficiency might be somewhat protective against hyperlipidaemia. 
The gene sets with MLP>3 (equivalent to uncorrected p<0.001) are shown in Table 2. Given that 
1454 sets were tested the critical value for the MLP to reach if a Bonferroni correction were applied 
would be log10(1454/0.05)=4.46, though this may be somewhat conservative given that some gene 
sets overlap with each other. This threshold is reached by the set HISTONE_MODIFICATION which 
contains 23 genes, one of which is HUWE1 (SLP=-6.15). No other genes in the set appear likely to 
have a direct role in risk of hyperlipidaemia and it appears that the result for the set is essentially 
driven by this single gene. The other set to be formally statistically significant is 
GENERATION_OF_PRECURSOR_METABOLITES_AND_ENERGY with MLP=5.47, implying that variants 
disrupting the function of one or more genes in this set can impact hyperlipidaemia risk. The set 
contains 120 genes, none of which individually produced an SLP with magnitude greater than 3. 
However Table 3 shows the members of this set which have individual SLP>=1.3, equivalent to an 
uncorrected p value of 0.05, and a number of them appear to be of interest, as detailed below. 
These genes all have negative SLPs, suggesting that rare variants impacting their functioning might 
tend to be protective against hyperlipidaemia. 
ADIPOQ (SLP=-1.37) codes for adiponectin, an adipokine which is expressed in adipocytes which 
influences fat metabolism, and common variants in the gene are associated with cardiovascular 
disease risk and lipid levels (Liu et al., 2018; Salazar-Tortosa et al., 2020; Wang et al., 2019; Zhang et 
al., 2019). Adiponectin has a hypoglycaemic effect and can reverse the insulin resistance associated 
with both lipoatrophy and obesity (Berg et al., 2001; Yamauchi et al., 2001). A rare intronic variant, 
rs74577862, has been reported to be associated with decreased levels of adiponectin and increased 
risk of atherosclerosis (Chen et al., 2017; UK10K Consortium et al., 2015).  
SURF1 (SLP=-1.71) codes for a protein involved in the assembly of cytochrome c oxidase complex 
and variants in it can cause Leigh syndrome, a fatal neurological condition (Lee et al., 2012). 
However mice completely lacking in Surf1 have increased longevity, lower adiposity and enhanced 
fatty acid oxidation. These findings suggest that variants which moderately impact SURF1 in humans 
might result in a more favourable lipid profile. 
ADRB3 (SLP=-1.81) codes for an adrenoceptor which promotes lipolysis and thermogenesis in 
response to sympathetic nerve stimulation and, as reviewed recently, the common variant Trp64Arg 
is associated with obesity and levels of serum lipids and adipokines (Luo et al., 2020).  
GYG2 (SLP=-2.00) has, like SURF1, been reported to be a cause of Leigh syndrome (Imagawa et al., 
2014). Knockdown in adipocytes causes reduction in total lipid and number of lipid droplets per cell 
as well as increased lipolysis (Kerr et al., 2019). 
PHKA1 (SLP=-2.29) and PHKA2 (SLP=-2.66) code for subunits of phosphorylase kinase and 
abnormalities in them are known to cause glycogen storage diseases with very variable phenotypes 
which can include hypoglycaemia, hypercholesterolaemia and hypertriglyceridaemia (Beauchamp et 
al., 2007; Preisler et al., 2012). 
Inspection of the detailed results for all the genes mentioned revealed that the SLPs obtained 
tended to arise from the cumulative effects of many rare variants. For no gene was it possible to 
identify any individual variant which appeared to be a main driver for the overall differences in 
burden scores between cases and controls. 
The SLPs for all genes and the MLPs for all gene sets are provided in supplementary tables S2 and S3. 
Discussion 
This analysis identifies one gene, HUWE1, which reaches conventional standards for statistical 
significance after correction for multiple testing and which could plausibly have a role in influencing 
risk of hyperlipidaemia. An increased burden of rare functional variants is found in controls versus 
cases, implying that impaired functioning reduces hyperlipidaemia risk and suggesting that 
theoretically it might be considered a target for lipid-lowering pharmacotherapy, although one 
caveat is that it can act as either a tumour suppressor or as an oncogene (Crawford et al., 2020).  
Other genes with uncorrected p values less than 0.001 are not formally statistically significant but 
might still be worth further investigation. The result for LDLR (SLP=3.67) demonstrates that even 
genes known to influence lipid levels may not achieve definitive results with a dataset of this size.  
Taking account of other information available, RBP2 (SLP=3.14), NPFFR1 (SLP=3.02) and ACOT9 
(SLP=-3.19) are especially noteworthy. 
The results from the gene set analysis confirm that the variants tending to affect genes involved in 
metabolism and energy influence hyperlipidaemia risk, which is of course a biologically plausible 
result and one which can be regarded as fairly robust given that the MLP obtained, 5.47, is formally 
statistically significant after correction for testing of multiple gene sets. However it is difficult to say 
exactly which genes are involved in driving this result. The results for ADIPOQ (SLP=-1.37) and ADRB3 
(SLP=-1.81) are in the opposite direction to what might be expected, since the literature would 
predict that disruption of these genes could promote hyperlipidaemia and one would expect 
multiple variants having major effects on function to tend to more often impair function than 
enhance it. On the other hand, it seems plausible that reduced function of SURF1 (SLP=-1.71) or 
GYG2 (SLP=-2.00) could be protective. 
With the exception of STAT5B, for none of the genes of interest has there been a report of 
association of hyperlipidaemia with nearby common SNPs such as are used in GWAS panels. 
Selection pressures mean that variants having major effects on function tend to be very rare and 
hence are not included in such panels. For all of the genes noted, the overall effect detected derives 
from a large number of rare variants and hence one would only expect to observe an association 
with a common SNP if a substantially larger number of these variants were in linkage disequilibrium 
with one allele of the SNP than the other. 
A major weakness of this kind of approach is that it is currently not possible to confidently predict in 
advance which DNA variants will actually have major effects on protein function. This means that at 
best one can obtain some kind of statistical signal suggesting that a gene may be involved in 
affecting a particular phenotype but as each variant is individually rare one cannot usually draw 
firmer conclusions than this. To illustrate this point, we can note that the method produces some 
support for the involvement of LDLR but essentially none at all for APOB, PCSK9 or HMGCR, three 
genes which are known to affect lipid levels. There may well be some rare variants impacting 
function in these genes but any signal present may be swamped by other variants which are 
weighted highly but which are not, in fact, relevant. There are other ways in which variants could be 
weighted, for examply using other software or taking into account features such as regional 
conservation, but we do not have a scheme which we know in advance is optimal and attempting to 
apply multiple different weighting schemes would risk generating false positive results by chance. 
Overall, this analysis demonstrates that next generation sequence data does not provide a magic 
bullet for identifying rare variants influencing complex traits, even with large sample sizes. On the 
other hand, there are some potentially interesting results which are close to the threshold for formal 
significance such that it would be quite reasonable to expect that further definitive results could be 
obtained from a somewhat larger sample. The present results should be regarded as hypothesis-
generating rather than conclusive. At time of writing, exome sequencing of 200,000 UK Biobank 
samples has been completed and this data should be released soon and may well provide further 
insights. 
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Table 1 Genes with absolute value of SLP exceeding 3 or more (equivalent to p<0.001) for test of 
association of weighted burden score with hyperlipidaemia. 
Gene symbol SLP Gene name 
GPR108 4.37 G Protein-Coupled Receptor 108 
LOC112268007 4.35 GRM3 Antisense RNA 1 
LOC107984851 3.77 Uncharacterized LOC107984851 
C16orf71 3.76 Chromosome 16 Open Reading Frame 71 
LDLR 3.67 Low Density Lipoprotein Receptor 
CLLU1OS 3.44 CLLU1 Antisense RNA 1 
DCUN1D4 3.35 Defective In Cullin Neddylation 1 Domain Containing 4 
LOC101927854 3.34 Uncharacterized LOC101927854 
F11R 3.19 F11 Receptor 
UNC5A 3.18 Unc-5 Netrin Receptor A 
FAM219B 3.14 Family With Sequence Similarity 219 Member B 
RBP2 3.14 Retinol Binding Protein 2 
STAT5B 3.11 Signal Transducer And Activator Of Transcription 5B 
NPFFR1 3.02 Neuropeptide FF Receptor 1 
TRAPPC5 3.02 Trafficking Protein Particle Complex 5 
AOX1 -3.01 Aldehyde Oxidase 1 
RAB9B -3.01 RAB9B, Member RAS Oncogene Family 
MAN2B2 -3.07 Mannosidase Alpha Class 2B Member 2 
HCFC1 -3.08 Host Cell Factor C1 
ZFR -3.08 Zinc Finger RNA Binding Protein 
PLP1 -3.13 Proteolipid Protein 1 
JDP2 -3.14 Jun Dimerization Protein 2 
SCML2 -3.17 Scm Polycomb Group Protein Like 2 
ACOT9 -3.19 Acyl-CoA Thioesterase 9 
PCDHB10 -3.23 Protocadherin Beta 10 
SLC9A7 -3.23 Solute Carrier Family 9 Member A7 
ATP11C -3.25 ATPase Phospholipid Transporting 11C 
RPS6KA3 -3.25 Ribosomal Protein S6 Kinase A3 
ZNF709 -3.27 Zinc Finger Protein 709 
GK -3.31 Glycerol Kinase 
CYTL1 -3.34 Cytokine Like 1 
ATRX -3.43 ATRX Chromatin Remodeler 
WDFY4 -3.43 WDFY Family Member 4 
XPNPEP2 -3.48 X-Prolyl Aminopeptidase 2 
ATP7A -3.51 ATPase Copper Transporting Alpha 
AMELX -3.60 Amelogenin X-Linked 
CFAP47 -3.82 Cilia And Flagella Associated Protein 47 
TENM1 -3.90 Teneurin Transmembrane Protein 1 
THOC2 -4.17 THO Complex 2 
USP9X -4.78 Ubiquitin Specific Peptidase 9 X-Linked 
MTMR1 -5.31 Myotubularin Related Protein 1 
CXorf56 -5.61 Chromosome X Open Reading Frame 56 
HUWE1 -6.15 HECT, UBA And WWE Domain Containing E3 Ubiquitin Protein Ligase 1 
 
  
Table 2 Gene sets with value of MLP of 3 or more (equivalent to p<=0.01) for test of association of 
weighted burden scores with hyperlipidaemia. 
























Table 3 Genes within GENERATION_OF_PRECURSOR_METABOLITES_AND_ENERGY with absolute 
value of SLP exceeding 1.3 (equivalent to p<0.05) for test of association of weighted burden score 
with hyperlipidaemia. 
Gene symbol SLP Gene name 
PDHB 2.82 Pyruvate Dehydrogenase E1 Subunit Beta 
ALDH5A1 2.38 Aldehyde Dehydrogenase 5 Family Member A1 
SLC25A3 1.62 Solute Carrier Family 25 Member 3 
ASIP 1.37 Agouti Signaling Protein 
XYLB -1.31 Xylulokinase 
ADIPOQ -1.37 Adiponectin, C1Q And Collagen Domain Containing 
AVP -1.46 Arginine Vasopressin 
SURF1 -1.71 SURF1 Cytochrome C Oxidase Assembly Factor 
ALDH9A1 -1.72 Aldehyde Dehydrogenase 9 Family Member A1 
ADRB3 -1.81 Adrenoceptor Beta 3 
ENOX2 -1.83 Ecto-NOX Disulfide-Thiol Exchanger 2 
AKR1C3 -1.84 Aldo-Keto Reductase Family 1 Member C3 
GLUD2 -1.99 Glutamate Dehydrogenase 2 
GYG2 -2.00 Glycogenin 2 
PHKA1 -2.29 Phosphorylase Kinase Regulatory Subunit Alpha 1 
HCCS -2.56 Holocytochrome C Synthase 






QQ plot of SLPs obtained for weighted burden analysis of 22,028 genes for association with 
hyperlipidaemia showing observed against expected SLP for each gene.  
 
  
Supplementary Table 1 
The table shows the weight accorded to each type of variant as annotated by VEP (McLaren et al., 
2016). 10 was added to this weight if the variant was annotated by Polyphen as possibly or probably 
damaging and 10 was added if SIFT annotated it as deleterious (Adzhubei et al., 2013; Kumar et al., 
2009). 
VEP annotation Weight 
intergenic_variant 1 
feature_truncation 3 
regulatory_region_variant 3 
feature_elongation 3 
regulatory_region_amplification 3 
regulatory_region_ablation 3 
TF_binding_site_variant 3 
TFBS_amplification 3 
TFBS_ablation 3 
downstream_gene_variant 3 
upstream_gene_variant 3 
non_coding_transcript_variant 3 
NMD_transcript_variant 3 
intron_variant 3 
non_coding_transcript_exon_variant 3 
3_prime_UTR_variant 5 
5_prime_UTR_variant 5 
mature_miRNA_variant 5 
coding_sequence_variant 5 
synonymous_variant 5 
stop_retained_variant 5 
incomplete_terminal_codon_variant 5 
splice_region_variant 5 
protein_altering_variant 10 
missense_variant 10 
inframe_deletion 15 
inframe_insertion 15 
transcript_amplification 15 
start_lost 15 
stop_lost 15 
frameshift_variant 20 
stop_gained 20 
splice_donor_variant 20 
splice_acceptor_variant 20 
transcript_ablation 20 
  
 
